The Effect of Physiotherapy Program in Scleroderma Patients
Launched by ISTANBUL UNIVERSITY · Nov 26, 2019
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Scleroderma is an autoimmune connective tissue disease with fibrosis. Although its etiology and pathogenesis have not been clearly defined, it has a chronic course. It is estimated that scleroderma affects approximately 300,000 people in the United States. Most commonly, it affects adults and women.
When the current literature is examined, Landim et al. in their studies for the development and evaluation of hand exercises home program in patients with systemic scleroderma; They found that the 8-week home exercise program had positive effects on pain, function, mobility and strength. Antoni...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having been diagnosed with scleroderma
- • Stability of medical treatments
- • To be able to adapt to the exercises
- Exclusion Criteria:
- • The patient has a history of neurological disease or trauma that may affect his symptoms
- • Systemic involvement that affects the treatment process
- • Being in the active phase of the disease
About Istanbul University
Istanbul University, a leading institution in Turkey, is dedicated to advancing healthcare through rigorous clinical research and education. Renowned for its commitment to scientific excellence and innovation, the university sponsors clinical trials that aim to enhance medical knowledge and improve patient outcomes. With a diverse team of researchers and healthcare professionals, Istanbul University fosters collaboration across disciplines to explore new therapeutic interventions and contribute to global health advancements. Its robust infrastructure and ethical standards ensure the highest quality in clinical trial management, making it a key player in the field of medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Buyukcekmece, Turkey
Patients applied
Trial Officials
TUGBA CIVI KARAASLAN, MSc
Principal Investigator
Research Assistant
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials